Endonovo Therapeutics, Inc.
ENDV
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -26.98% | 181.70% | 399.62% | -639.67% | 60.40% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -108.31% | -62.11% | -87.30% | -50.12% | 1.29% |
| Total Other Non-Cash Items | 194.18% | -294.30% | -604.32% | 499.07% | -135.62% |
| Change in Net Operating Assets | -46.47% | -21.30% | -9.97% | 360.43% | 29.70% |
| Cash from Operations | 47.22% | 19.71% | -40.81% | 42.37% | 26.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -67.33% | -2.67% | -- | -86.32% | 0.00% |
| Total Debt Repaid | -566.67% | -28.57% | -666.67% | -28.57% | -118.07% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -77.69% | 27.99% | 89.69% | -57.05% | -11.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -241.13% | 136.17% | 141.54% | -128.68% | 925.00% |